A Randomized, Subject and Investigator Blinded, Placebo Controlled, Multi-center Study in Parallel Groups to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs LYS-006 (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 29 Oct 2019 Planned End Date changed from 17 Aug 2020 to 16 Nov 2020.
- 29 Oct 2019 Planned primary completion date changed from 17 Aug 2020 to 16 Nov 2020.
- 18 Jul 2019 Planned End Date changed from 20 Jan 2020 to 17 Aug 2020.